These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29355006)

  • 1. [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
    Pérez-Rubio A; Eiros JM
    Rev Esp Quimioter; 2018 Feb; 31(1):43-52. PubMed ID: 29355006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
    Iannazzo S
    J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.
    Durando P; Icardi G; Ansaldi F
    Expert Opin Biol Ther; 2010 Apr; 10(4):639-51. PubMed ID: 20218923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis.
    Banzhoff A; Nacci P; Podda A
    Gerontology; 2003; 49(3):177-84. PubMed ID: 12679609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.
    Loperto I; Simonetti A; Nardone A; Triassi M
    Hum Vaccin Immunother; 2019; 15(5):1035-1047. PubMed ID: 30735465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.